POSTECH 생명과학과

Faculty and research

Faculty
and research
Research highlight
리서치하이라이트

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhanci…

  • 저널명SCIENCE ADVANCES
    • 담당교수Seung-Woo Lee
    • 조회452
    • 작성자최고관리자
    • 2021-01-18

    본문

    8cef13c416b20df3cb3b4b220786703a_1610947185_1933.png 

     

    ■Abstract
    Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict the 4-1BB stimulation in tumors. B7-H3×m4-1BB elicited a 4-1BB–dependent antitumor response in hB7-H3–overexpressing tumor models without systemic toxicity. BsAb primarily targets CD8 T cells in the tumor and increases their proliferation and cytokine production. Among the CD8 T cell population in the tumor, 4-1BB is solely expressed on PD-1+Tim-3+ “terminally differentiated” subset, and bsAb potentiates these cells for eliminating the tumor. Furthermore, the combination of bsAb and PD-1 blockade synergistically inhibits tumor growth accompanied by further increasing terminally differentiated CD8 T cells. B7-H3×h4-1BB also shows antitumor activity in h4-1BB–expressing mice. Our data suggest that B7-H3×4-1BB is an effective and safe therapeutic agent against B7-H3–positive cancers as monotherapy and combination therapy with PD-1 blockade. 


    Top